Ybrain's Electronic Medicine 'Mindsteem' to Be Sold by Chong Kun Dang

Kim Young-joo, CEO of Chong Kun Dang, and Lee Ki-won, CEO of Ybrain (from left), are posing for a commemorative photo on the 30th after signing a domestic joint promotion contract for 'Mindsteem'.
[Photo by Ybrain]

[Asia Economy Reporter Lee Chun-hee] Mental health digital therapeutics platform company Ybrain announced on the 31st that it signed a domestic joint promotion contract for the depression digital therapeutics 'Mindsteem' with Chong Kun Dang on the 30th.

This joint promotion contract is structured so that Chong Kun Dang exclusively supplies Ybrain's Mindsteem and sells it to psychiatric clinics in Korea. Chong Kun Dang will conduct various marketing activities such as academic activities and product education to facilitate the smooth sales of Mindsteem, while Ybrain will be responsible for product installation, customer inquiries and claims, consumer response, and after-sales service including repairs for the Mindsteem units ultimately sold by Chong Kun Dang.

Mindsteem was selected as a new medical technology exemption target in June last year and began to be prescribed as a non-reimbursable treatment. It has been introduced in 70 hospitals to date, achieving a cumulative prescription count of 15,000. A multicenter clinical trial conducted in 2020 at six university hospitals in Korea showed that applying Mindsteem alone for 30 minutes daily over six weeks resulted in a remission rate of depressive symptoms of 62.8%, which is a higher symptom improvement rate compared to the approximately 50% remission rate of conventional antidepressants.

At the signing ceremony, the Blue Band campaign to raise awareness about depression, jointly conducted by Ybrain and the Korean Neuropsychiatric Association, was also introduced. Chong Kun Dang plans to actively cooperate with the Blue Band campaign, which promotes early diagnosis and treatment of depression in Korea, starting from this contract.

Lee Ki-won, CEO of Ybrain, said, “The joint promotion with Chong Kun Dang will be a signal for the full-scale domestic distribution and expansion of Mindsteem,” adding, “Based on this contract, we will strengthen cooperation on the Blue Band campaign conducted with the Neuropsychiatric Association and work harder to foster an atmosphere for early diagnosis and treatment of depression in Korea.” Kim Young-joo, CEO of Chong Kun Dang, also stated, "Mindsteem will be a highly satisfactory treatment option in the brain science digital healthcare field,” and “We will leap forward as a leading company with global competitiveness pioneering new business areas such as digital medicine and personalized pharmaceuticals.”